Pharma: Page 46
-
Permission granted by Bristol-Myers Squibb
Bristol Myers bets $4B on Turning Point and its targeted cancer drugs
While priced at a significant premium, the deal values Turning Point well below its peak valuation last year, a potential sign biotechs might be adjusting their expectations amid the sector's downturn.
By Jonathan Gardner • Updated June 3, 2022 -
Courtesy of Regeneron Pharmaceuticals
Regeneron buys control of cancer drug Libtayo from Sanofi
The biotech, which has been partnered with Sanofi for years, will pay $900 million upfront to gain sole control of the cancer immunotherapy.
By Jonathan Gardner • Updated June 2, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Permission granted by Bristol-Myers Squibb
Bristol Myers' autoimmune drug shows potential in lupus
Positive Phase 2 results could help boost company executives' arguments that the drug, called deucravacitinib and under FDA review in psoriasis, will become a top-seller.
By Jonathan Gardner • June 1, 2022 -
Warren Little via Getty Images
Pfizer to exit GSK consumer health joint venture after spinoff
The pharma currently holds a 32% stake in the business, which is set to become a standalone company that will trade on the London Stock Exchange beginning in July.
By Kristin Jensen • June 1, 2022 -
Roche SMA drug approved in youngest infants, challenging Novartis and Biogen
Evrysdi, the only oral drug for the neurodegenerative disorder, can now be used to treat babies younger than 2 months who have been identified through newborn screening.
By Jonathan Gardner • May 31, 2022 -
Erik S. Lesser via Getty Images
Merck study results signal blood cancer potential for new type of immunotherapy
Bristol Myers beat Merck to the first approval of a so-called LAG-3 inhibitor. But Merck is advancing its own and data to be presented at ASCO show it could help treat Hodgkin's lymphoma.
By Jonathan Gardner • May 26, 2022 -
Courtesy of Eli Lilly
Lilly to expand, add jobs with two new factories in Indiana
The drugmaker is spending $2 billion on the new facilities, which will be staffed with up to 500 new corporate positions and support production of its pipeline of new products.
By Kristin Jensen • May 26, 2022 -
Pfizer pledges not-for-profit sale of medicines in low-income countries
The pharma has been criticized for not doing enough to make its COVID-19 vaccine and pill available globally. The new initiative commits Pfizer to supplying current and future branded medicines at lower cost to 45 countries.
By Jonathan Gardner • May 25, 2022 -
Jeenah Moon via Getty Images
Pfizer, Lilly bolster cases for experimental ulcerative colitis drugs
The two companies are each developing new types of medicines that they hope can soon win FDA approval for treating the autoimmune disease.
By Ned Pagliarulo • May 24, 2022 -
Courtesy of Pfizer
Pfizer says 3 doses of its COVID-19 vaccine works in youngest children
The drugmaker, along with partner BioNTech, plans to submit the new data to the FDA this week. The agency has scheduled a meeting for outside experts to review the data in mid-June.
By Jonathan Gardner • May 23, 2022 -
Getty Images
Sponsored by GoodRxCommon barriers to patient engagement: What's your strategy?
As with treatment, and even adherence, there is no 'one size fits all' when it comes to patient engagement.
May 23, 2022 -
Bayer backs out of Atara cell therapy deal
The German drugmaker will hand back rights to two CAR-T cell therapies it was developing with Atara, which said it would reassess its strategy for the programs.
By Ned Pagliarulo • May 20, 2022 -
AbbVie asks FDA to approve Parkinson’s treatment
The company believes the treatment, which uses prodrug versions of two commonly used Parkinson's medications, could be a longer-lasting option for patients and blockbuster product for AbbVie.
By Jacob Bell • May 20, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers' Opdivo comes up short in bladder cancer trial
The top-selling immunotherapy failed to improve survival in first-line urothelial carcinoma, a tumor type that's proved difficult to treat with drugs like Opdivo.
By Ned Pagliarulo • May 16, 2022 -
Permission granted by Vetter Pharma
Sponsored by Vetter PharmaMaking sub-visible particles visible
Sub-visible particles can lower the effectiveness of a drug, which is why regulatory authorities are demanding processes be developed, validated and set up in such a way as to minimize all forms of contamination.
By Dr. Melanie Zerulla-Wernitz, Head of the Analytical Science Laboratory, Vetter Pharma • May 16, 2022 -
Courtesy of Eli Lilly
Lilly wins FDA approval for new kind of diabetes drug
Tirzepatide, now branded as Mounjaro, helped improve blood sugar control in testing and was shown to have powerful weight loss effects as well, making it one of the most closely watched drugs in Lilly's pipeline.
By Jonathan Gardner • Updated May 16, 2022 -
Jacob Bell/BioPharma Dive
FDA approves oral version of Mitsubishi's ALS drug
Called Radicava ORS, this version is taken by mouth rather than via an hourlong infusion, which may help improve the drug's convenience and use.
By Jacob Bell • May 13, 2022 -
Permission granted by Bristol-Myers Squibb
Key Bristol Myers drug holds up in long-term psoriasis study
Deucravacitnib, forecast by Bristol Myers to hit $4 billion in peak sales, is under FDA review with an approval decision due by September. The agency's view of its safety will be key to its future.
By Jonathan Gardner • May 12, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers acquires BridgeBio drug aimed at emerging cancer target
The pharma will pay $90 million to license BridgeBio's experimental candidate, joining a lengthening list of large drugmakers aiming to treat cancer by blocking a protein called SHP2.
By Ned Pagliarulo • May 12, 2022 -
Getty Images
Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class
A treatment combination involving Roche's anti-TIGIT medicine tiragolumab missed its goal in a Phase 3 lung cancer study that was viewed as a proof point for the drug class.
By Ben Fidler • May 11, 2022 -
Dan Kitwood via Getty Images
Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs
The deal, which hands Pfizer full rights to the biotech's fast-selling Nurtec ODT, could provide a much needed spark for the sector after months of stock market declines.
By Ben Fidler , Jacob Bell • Updated May 10, 2022 -
Mario Tama via Getty Images
J&J ends hepatitis B, HPV vaccine work with Bavarian Nordic
The companies' hepatitis B program never reached clinical testing, while J&J said it would no longer develop an HPV vaccine because of the "widespread uptake" of effective shots from other companies.
By Ned Pagliarulo • May 9, 2022 -
Permission granted by Novartis
Novartis suspends production of two radiopharmaceutical drugs over quality concerns
Due to potential issues in manufacturing, the pharma is halting deliveries of two cancer drugs, Lutathera and Pluvicto, in the U.S. and Canada, a setback for a business in which the company has invested heavily.
By Ned Pagliarulo • May 6, 2022 -
Istockphoto.com/RyanKing999
Sponsored by Acceleration PointDigital key opinion leaders: who are they?
As scientific discussions increase online, Medical Affairs teams need ways to listen to conversations.
May 2, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers wins FDA approval for first drug to treat inherited heart condition
Bristol Myers paid $13 billion to acquire the drug's maker, MyoKardia, and expects it to become a blockbuster. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant's lofty forecast.
By Jonathan Gardner • April 28, 2022
Previous
